This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ringdén, O. Articles by Frassoni, F. Search for Related Content PubMed PubMed Citation Articles by Ringdén, O. Articles by Frassoni, F. Social Bookmarking                            What's this?

Transplantation of Peripheral Blood Stem Cells as Compared With Bone Marrow From HLA-Identical Siblings in Adult Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

From the Centre for Allogeneic Stem Cell Transplantation, Huddinge, Sweden; Centre International Greffes de Moelle, Hôpital Saint-Antoine, European Group for Blood and Marrow Transplantation Data Centre, Institut des Cordeliers, and Department of Hematology, Hôpital Saint-Louis, Paris, France; Bone Marrow Transplant Unit, Ospedale San Martino, Genova, and Institute of Hematology, University La Sapienza, Rome, Italy; Department of Bone Marrow Transplantation, University Hospital, Essen, and Department of Transfusion, University Ulm, Ulm, Germany; Bone Marrow Transplantation Center, Leiden, and Bone Marrow Transplantation Unit, Department of Hematology, Nijmegen, the Netherlands; and Department of Hematology, Ankara University, Ankara, Turkey.

Address reprint requests to Olle Ringdén, MD, PhD, Centre for Allogeneic Stem Cell Transplantation, Huddinge University Hospital, F79, SE-141 86 Stockholm, Sweden; email: Olle.Ringden{at}impi.ki.se

PURPOSE: Several studies show that allogeneic peripheral blood stem cells (PBSCs) engraft more rapidly than bone marrow (BM). However, the data are inconsistent with regard to acute and chronic graft-versus-host disease (GVHD), relapse, transplant-related mortality (TRM), and leukemia-free survival (LFS).

PATIENTS AND METHODS: Between January 1994 and December 2000, 3,465 adult patients (older than 15 years of age) were reported to the European Group for Blood and Marrow Transplantation Registry from 224 centers. Among acute myeloid leukemia (AML) patients, 1,537 patients received BM and 757 patients received PBSC. In acute lymphoblastic leukemia (ALL) patients, the corresponding figures were 826 versus 345 patients who were analyzed for engraftment, GVHD, TRM, relapse, LFS, and survival.

RESULTS: In multivariate analysis, the recovery of neutrophils and platelets was faster with PBSC than with BM (P < .0001). Chronic GVHD was associated with PBSC in patients with AML (relative risk [RR], 2.11; 95% confidence interval, 1.66 to 2.7; P < .0001) and ALL (RR, 1.56; 95% confidence interval, 1.09 to 2.27; P = .02). PBSC versus BM in patients with AML or ALL was not significantly associated with acute GVHD, TRM, relapse, survival, or LFS. In multivariate analysis of patients with AML, factors significantly associated with improved LFS included first remission at transplant (P < .0001), promyelocytic leukemia (M3) versus other French-American-British types (P < .0001), and donor age below median 37 years (P = .02). In patients with ALL, first remission (P < .0001) and methotrexate included in the immunosuppressive regimen (P = .001) were associated with improved LFS.

CONCLUSION: Allogeneic PBSC results in faster neutrophil and platelet engraftment and a higher incidence of chronic GVHD than BM. However, acute GVHD, TRM, relapse, survival, and LFS were similar in patients receiving PBSCs versus BM.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. Morra, G. Barosi, A. Bosi, F. Ferrara, F. Locatelli, M. Marchetti, G. Martinelli, C. Mecucci, M. Vignetti, and S. Tura Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation Haematologica, January 1, 2009; 94(1): 102 - 112. [Abstract] [Full Text] [PDF]

				H. M. Lazarus and S. Luger Which Patients with Adult Acute Lymphoblastic Leukemia Should Undergo a Hematopoietic Stem Cell Transplantation? Case-Based Discussion Hematology, January 1, 2007; 2007(1): 444 - 452. [Abstract] [Full Text] [PDF]

				N. Schmitz, M. Eapen, M. M. Horowitz, M.-J. Zhang, J. P. Klein, J. D. Rizzo, F. R. Loberiza, A. Gratwohl, and R. E. Champlin Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation Blood, December 15, 2006; 108(13): 4288 - 4290. [Abstract] [Full Text] [PDF]

				C. Schmid, M. Schleuning, R. Schwerdtfeger, B. Hertenstein, E. Mischak-Weissinger, D. Bunjes, S. v. Harsdorf, C. Scheid, U. Holtick, H. Greinix, et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation Blood, August 1, 2006; 108(3): 1092 - 1099. [Abstract] [Full Text] [PDF]

				E. J. Jabbour, E. Estey, and H. M. Kantarjian Adult Acute Myeloid Leukemia Mayo Clin. Proc., February 1, 2006; 81(2): 247 - 260. [Abstract] [Full Text] [PDF]

				M. Krampera, L. Cosmi, R. Angeli, A. Pasini, F. Liotta, A. Andreini, V. Santarlasci, B. Mazzinghi, G. Pizzolo, F. Vinante, et al. Role for Interferon-{gamma} in the Immunomodulatory Activity of Human Bone Marrow Mesenchymal Stem Cells Stem Cells, February 1, 2006; 24(2): 386 - 398. [Abstract] [Full Text] [PDF]

				M. Stelljes, M. Bornhauser, M. Kroger, J. Beyer, M. C. Sauerland, A. Heinecke, B. Berning, C. Scheffold, G. Silling, T. Buchner, et al. Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia Blood, November 1, 2005; 106(9): 3314 - 3321. [Abstract] [Full Text] [PDF]

				T. Banovic, K. P. A. MacDonald, E. S. Morris, V. Rowe, R. Kuns, A. Don, J. Kelly, S. Ledbetter, A. D. Clouston, and G. R. Hill TGF-{beta} in allogeneic stem cell transplantation: friend or foe? Blood, September 15, 2005; 106(6): 2206 - 2214. [Abstract] [Full Text] [PDF]

				M. Eapen, M. M. Horowitz, J. P. Klein, R. E. Champlin, F. R. Loberiza Jr, O. Ringden, and J. E. Wagner Higher Mortality After Allogeneic Peripheral-Blood Transplantation Compared With Bone Marrow in Children and Adolescents: The Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry J. Clin. Oncol., December 15, 2004; 22(24): 4872 - 4880. [Abstract] [Full Text] [PDF]

				T. Ichinohe, T. Uchiyama, C. Shimazaki, K. Matsuo, S. Tamaki, M. Hino, A. Watanabe, M. Hamaguchi, S. Adachi, H. Gondo, et al. Feasibility of HLA-haploidentical hematopoietic stem cell transplantation between noninherited maternal antigen (NIMA)-mismatched family members linked with long-term fetomaternal microchimerism Blood, December 1, 2004; 104(12): 3821 - 3828. [Abstract] [Full Text] [PDF]

				E. S. Morris, K. P. A. MacDonald, V. Rowe, D. H. Johnson, T. Banovic, A. D. Clouston, and G. R. Hill Donor treatment with pegylated G-CSF augments the generation of IL-10-producing regulatory T cells and promotes transplantation tolerance Blood, May 1, 2004; 103(9): 3573 - 3581. [Abstract] [Full Text] [PDF]

				O. Ringden, M. Labopin, N.-C. Gorin, K. Le Blanc, V. Rocha, E. Gluckman, J. Reiffers, W. Arcese, J. M. Vossen, J.-P. Jouet, et al. Treatment With Granulocyte Colony-Stimulating Factor After Allogeneic Bone Marrow Transplantation for Acute Leukemia Increases the Risk of Graft-Versus-Host Disease and Death: A Study From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation J. Clin. Oncol., February 1, 2004; 22(3): 416 - 423. [Abstract] [Full Text] [PDF]

				D.C. Taussig, A.J. Davies, J.D. Cavenagh, H. Oakervee, D. Syndercombe-Court, S. Kelsey, J.A.L. Amess, A.Z.S. Rohatiner, T.A. Lister, and M.J. Barnett Durable Remissions of Myelodysplastic Syndrome and Acute Myeloid Leukemia After Reduced-Intensity Allografting J. Clin. Oncol., August 15, 2003; 21(16): 3060 - 3065. [Abstract] [Full Text] [PDF]